Chronic granulomatous disease (CGD): Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management

Document Type : Review


1 Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran

2 Alborz University of Medical Sciences, Karaj, Iran.

3 Alborz University of Medical Sciences, Karaj, Iran

4 Department of Sports and Exercise Medicine, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, Iran Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

5 Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran



Chronic granulomatous disease (CGD) is a relatively rare inborn error of immune system caused by defects in the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex which leads to impaired production of reactive oxygen species (ROS) and ineffective phagocyte function. Genetic defects of any of proteinaceous components of NADPH oxidase complex results in CGD. The most common type of CGD (65-70%) is caused by X-linked mutations in the CYBB gene encoding gp91phox, followed by autosomal recessive mutations in the NCF1, NCF2, CYBA and NCF4 genes encoding p47phox, p67phox, p22phox, and p40phox, respectively. Dihydrorhodamine (DHR) 123 oxidation and nitroblue tetrazolium (NBT) tests are both used for the diagnosis of CGD that should be confirmed by genetic testing. CGD patients generally present with recurrent infections caused by uncommon pathogens like aspergillus, staphylococcus aureus, burkholderia cepacia, serratia marcescens, Aspergillus species and nocardia. They manifest with deep seated abscess formation, genitourinary and gastrointestinal granuloma development, autoimmunity and malignancy. Apart from comprehensive treatment of acute infections, management of CGD is based on reducing bacterial and fungal infections in addition to minimizing the inflammatory symptoms. Antibiotics, anti-fungal and IFN-γ are used for prophylaxis. Allogeneic hematopoietic stem cell transplantation from a human leucocyte antigen identical donor is currently the only proven curative treatment for CGD. Gene therapy is considered an alternative, novel therapeutic approach in near future.


1. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4):e5234. 2. Winkelstein JA, Marino MC, Johnston RB, Jr., Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155-69. 3. Arnadottir GA, Norddahl GL, Gudmundsdottir S, Agustsdottir AB, Sigurdsson S, Jensson BO, et al. A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease. Nat Commun. 2018;9(1):4447. 4. Roos D, Kuhns DB, Maddalena A, Roesler J, Lopez JA, Ariga T, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis. 2010;45(3):246-65. 5. Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010;363(27):2600-10. 6. Jones LB, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol. 2008;152(2):211-8. 7. Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60(8):1176-83. 8. Rider NL, Jameson MB, Creech CB. Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S2-S5. 9. Arnold DE, Heimall JR. A Review of Chronic Granulomatous Disease. Adv Ther. 2017;34(12):2543-57. 10. Anjani G, Vignesh P, Joshi V, Shandilya JK, Bhattarai D, Sharma J, et al. Recent advances in chronic granulomatous disease. Genes Dis. 2020;7(1):84-92. 11. Rider N, Jameson M, Creech C. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S2-S5. 12. Leiding JW, Holland SM. Chronic granulomatous disease. Stiehm’s Immune Deficiencies: Elsevier; 2020. p. 829-47. 13. Reeves EP, Lu H, Jacobs HL, Messina CG,Bolsover S, Gabella G, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature. 2002;416(6878):291-7. 14. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000;79(3):170-200. 15. Yu HH, Yang YH, Chiang BL. Chronic Granulomatous Disease: a Comprehensive Review. Clin Rev Allergy Immunol. 2020:1-13. 16. Hoffman R. Hematology : basic principles and practice. 6th ed. Philadelphia, PA: Saunders/Elsevier; 2013. xxxi, 2343 p. p. 17. Salvator H, Mahlaoui N, Catherinot E, Rivaud E, Pilmis B, Borie R, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. Eur Respir J. 2015;45(6):1613-23. 18. Falcone EL, Holland SM. Invasive fungal infection in chronic granulomatous disease: insights into pathogenesis and management. Curr Opin Infect Dis. 2012;25(6):658-69. 19. Beaute J, Obenga G, Le Mignot L, Mahlaoui N, Bougnoux ME, Mouy R, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J. 2011;30(1):57-62. 20. Blumental S, Mouy R, Mahlaoui N, Bougnoux ME, Debre M, Beaute J, et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis. 2011;53(12):e159-69. 21. Desjardins A, Coignard-Biehler H, Mahlaoui N, Frange P, Bougnoux ME, Blanche S, et al. [Chronic granulomatous disease: pathogenesis and therapy of associated fungal infections]. Med Sci (Paris). 2012;28(11):963-9. 22. Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, Masur H, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. 2007;45(6):673-81. 23. Liese J, Kloos S, Jendrossek V, Petropoulou T, Wintergerst U, Notheis G, et al. Longterm follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr. 2000;137(5):687-93. 24. Magnani A, Brosselin P, Beaute J, de Vergnes N, Mouy R, Debre M, et al. Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. J Allergy Clin Immunol. 2014;134(3):655-62 e8. 25. Spagnolo P, Rossi G, Cavazza A, Bonifazi M, Paladini I, Bonella F, et al. Hypersensitivity Pneumonitis: A Comprehensive Review. J Investig Allergol Clin Immunol. 2015;25(4):237- 50; quiz follow 50. 26. Buchvald F, Petersen BL, Damgaard K, Deterding R, Langston C, Fan LL, et al. Frequency, treatment, and functional outcome in children with hypersensitivity pneumonitis. Pediatr Pulmonol. 2011;46(11):1098-107. 27. Katsuya Y, Hojo M, Kawai S, Kawai T, Onodera M, Sugiyama H. Chronic granulomatous disease with pulmonary mass-like opacities secondary to hypersensitivity pneumonitis: a case report. J Med Case Rep. 2014;8:242. 28. Segerer F, Morbach H, Hassold N, Kleinert S, Tony HP, Roesler J, et al. A 58-year-old man with respiratory insufficiency after a 50-year history of hypersensitivity pneumonitis and pulmonary Aspergillus infections. J Allergy Clin Immunol Pract. 2013;1(6):677-80. 29. Esenboga S, Emiralioglu N, Cagdas D, Erman B, De Boer M, Oguz B, et al. Diagnosis of Interstitial Lung Disease Caused by Possible Hypersensitivity Pneumonitis in a Child: Think CGD. J Clin Immunol. 2017;37(3):269-72. 30. Liu H, Liu J, Li H, Peng Y, Zhao S. Mimicking hypersensitivity pneumonitis as an uncommon initial presentation of chronic granulomatous disease in children. Orphanet J Rare Dis. 2017;12(1):169. 31. Liu H, Yang H, Li H, Liu J, Zhao S. Hyper-sensitive Pneumonitis: an Initial Presentation of Chronic Granulomatous Disease in a Child. J Clin Immunol. 2018;38(2):155-8. 32. Kawai T, Watanabe N, Yokoyama M, Nakazawa Y, Goto F, Uchiyama T, et al. Interstitial lung disease with multiple microgranulomas in chronic granulomatous disease. J Clin Immunol. 2014;34(8):933-40. 33. Ameratunga R, Woon ST, Vyas J, Roberts S. Fulminant mulch pneumonitis in undiagnosed chronic granulomatous disease: a medical emergency. Clin Pediatr (Phila). 2010;49(12):1143-6. 34. van de Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, van der Meer JW, et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A. 2010;107(7):3030-3. 35. Bains SN, Judson MA. Allergic bronchopulmonary aspergillosis. Clin Chest Med. 2012;33(2):265-81. 36. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009;135(3):805-26. 37. Chakrabarti A, Sethi S, Raman DS, Behera D. Eight-year study of allergic bronchopulmonary aspergillosis in an Indian teaching hospital. Mycoses. 2002;45(8):295-9. 38. Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. 39. Malbora B, Aksoylar S, Ozdemir HH, Ozdemir S, Kansoy S. A Case of Allergic Broncopulmonary Aspergillosis Associated With Hematopoietic Stem Cell Transplantation Due to Chronic Granulomatous Disease. J Pediatr Hematol Oncol. 2019;41(3):e161-e3. 40. Lugo Reyes SO, Ramirez-Vazquez G, Cruz Hernandez A, Medina-Torres EA, Ramirez-Lopez AB, Espana-Cabrera C, et al. Clinical Features, Non-Infectious Manifestations and Survival Analysis of 161 Children with Primary Immunodeficiency in Mexico: A Single Center Experience Over two Decades. J Clin Immunol. 2016;36(1):56-65. 41. Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol. 2007;148(1):79-84. 42. Battersby AC, Braggins H, Pearce MS, Cale CM, Burns SO, Hackett S, et al. Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom. J Allergy Clin Immunol. 2017;140(2):628-30 e6. 43. Thompson EN, Soothill JF. Chronic granulomatous disease: quantitative clinicopathological relationships. Arch Dis Child. 1970;45(239):24-32. 44. Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol. 2003;73(5):591-9. 45. Sanford AN, Suriano AR, Herche D, Dietzmann K, Sullivan KE. Abnormal apoptosis in chronic granulomatous disease and autoantibody production characteristic of lupus. Rheumatology (Oxford). 2006;45(2):178-81. 46. Carneiro-Sampaio M, Liphaus BL, Jesus AA, Silva CA, Oliveira JB, Kiss MH. Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies. J Clin Immunol. 2008;28 Suppl 1:S34-41. 47. Foster CB, Lehrnbecher T, Mol F, Steinberg SM, Venzon DJ, Walsh TJ, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest.1998;102(12):2146-55. 48. Manzi S, Urbach AH, McCune AB, Altman HA, Kaplan SS, Medsger TA, Jr., et al. Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. Arthritis Rheum. 1991;34(1):101-5. 49. Stalder JF, Dreno B, Bureau B, Hakim J. Discoid lupus erythematosus-like lesions in an autosomal form of chronic granulomatous disease. Br J Dermatol. 1986;114(2):251-4. 50. Badolato R, Notarangelo LD, Plebani A, Roos D. Development of systemic lupus erythematosus in a young child affected with chronic granulomatous disease following withdrawal of treatment with interferon-gamma. Rheumatology (Oxford). 2003;42(6):804-5. 51. Gallin JI, Buescher ES, Seligmann BE, Nath J, Gaither T, Katz P. NIH conference. Recent advances in chronic granulomatous disease. Ann Intern Med. 1983;99(5):657-74. 52. Matsuura R, Kagosaki Y, Tanaka Y, Kashiwa H, Sakano T, Kobayashi Y, et al. A female case of chronic granulomatous disease (CGD) associated with chronic idiopathic thrombocytopenic purpura. Hiroshima J Med Sci. 1980;29(2):83-6. 53. Frifelt JJ, Schonheyder H, Valerius NH, Strate M, Starklint H. Chronic granulomatous disease associated with chronic glomerulonephritis. Acta Paediatr Scand. 1985;74(1):152-7. 54. van Rhenen DJ, Koolen MI, Feltkamp-Vroom TM, Weening RS. Immune complex glomerulonephritis in chronic granulomatous disease. Case report of an eighteen-year-old girl. Acta Med Scand. 1979;206(3):233-7. 55. De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol. 2008;122(6):1097-103. 56. Macedo F, McHugh K, Goldblatt D. Pericardial effusions in two boys with chronic granulomatous disease. Pediatr Radiol. 1999;29(11):820-2. 57. Lee BW, Yap HK. Polyarthritis resembling juvenile rheumatoid arthritis in a girl with chronic granulomatous disease. Arthritis Rheum. 1994;37(5):773-6. 58. Schmitt CP, Scharer K, Waldherr R, Seger RA, Debatin KM. Glomerulonephritis associated with chronic granulomatous disease and systemic lupus erythematosus. Nephrol Dial Transplant. 1995;10(6):891-5. 59. Narsipur SS, Shanley PF. IgA nephropathy in a patient with chronic granulomatous disease. J Nephrol. 2002;15(6):713-5. 60. De Ravin SS, Naumann N, Robinson MR, Barron KS, Kleiner DE, Ulrick J, et al. Sarcoidosis in chronic granulomatous disease. Pediatrics. 2006;117(3):e590-5. 61. Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O’Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114(2):462-8. 62. Kang EM, Marciano BE, DeRavin S, Zarember KA, Holland SM, Malech HL. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2011;127(6):1319-26; quiz 27-8. 63. Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). J Clin Immunol. 2008;28 Suppl 1:S67-72. 64. van de Geer A, Cuadrado E, Slot MC, van Bruggen R, Amsen D, Kuijpers TW. Regulatory T cell features in chronic granulomatous disease. Clin Exp Immunol. 2019;197(2):222-9. 65. Kobayashi SD, Voyich JM, Braughton KR, Whitney AR, Nauseef WM, Malech HL, et al. Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease. J Immunol. 2004;172(1):636-43. 66. Damen GM, van Krieken JH, Hoppenreijs E, van Os E, Tolboom JJ, Warris A, et al. Overlap, common features, and essential differences in pediatric granulomatous inflammatorybowel disease. J Pediatr Gastroenterol Nutr. 2010;51(6):690-7. 67. Khangura SK, Kamal N, Ho N, Quezado M, Zhao X, Marciano B, et al. Gastrointestinal Features of Chronic Granulomatous Disease Found During Endoscopy. Clin Gastroenterol Hepatol. 2016;14(3):395-402 e5. 68. Markowitz JF, Aronow E, Rausen AR, Aiges H, Silverberg M, Daum F. Progressive esophageal dysfunction in chronic granulomatous disease. J Pediatr Gastroenterol Nutr. 1982;1(1):145-9. 69. Golioto M, O’Connor JB. Esophageal dysmotility in an adult with chronic granulomatous disease. J Clin Gastroenterol. 2001;33(4):330-2. 70. Ruiz-Contreras J, Bastero R, Serrano C, Benavent MI, Martinez A. Oesophageal narrowing in chronic granulomatous disease. Eur J Radiol. 1998;27(2):149-52. 71. Alimchandani M, Lai JP, Aung PP, Khangura S, Kamal N, Gallin JI, et al. Gastrointestinal histopathology in chronic granulomatous disease: a study of 87 patients. Am J Surg Pathol. 2013;37(9):1365-72. 72. Falcone EL, Holland SM. Gastrointestinal Complications in Chronic Granulomatous Disease. Methods Mol Biol. 2019;1982:573-86. 73. Liu S, Russo PA, Baldassano RN, Sullivan KE. CD68 expression is markedly different in Crohn’s disease and the colitis associated with chronic granulomatous disease. Inflamm Bowel Dis. 2009;15(8):1213-7. 74. Rosh JR, Tang HB, Mayer L, Groisman G, Abraham SK, Prince A. Treatment of intractable gastrointestinal manifestations of chronic granulomatous disease with cyclosporine. J Pediatr. 1995;126(1):143-5. 75. Noel N, Mahlaoui N, Blanche S, Suarez F, Coignard-Biehler H, Durieu I, et al. Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series. J Allergy Clin Immunol. 2013;132(4):997-1000 e1-4. 76. Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am J Gastroenterol. 2009;104(1):117-24. 77. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010;51(12):1429-34. 78. Gungor T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436-48. 79. Straughan DM, McLoughlin KC, Mullinax JE, Marciano BE, Freeman AF, Anderson VL, et al. The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease. Clin Infect Dis. 2018;66(9):1427-34. 80. Feld JJ, Hussain N, Wright EC, Kleiner DE, Hoofnagle JH, Ahlawat S, et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology. 2008;134(7):1917-26. 81. Cunningham-Rundles C, Cooper DL, Duffy TP, Strauchen J. Lymphomas of mucosal-associated lymphoid tissue in common variable immunodeficiency. Am J Hematol. 2002;69(3):171-8. 82. Mueller N. Overview of the epidemiology of malignancy in immune deficiency. J Acquir Immune Defic Syndr. 1999;21 Suppl 1:S5-10. 83. Weel EA, Redekop WK, Weening RS. Increased risk of malignancy for patients with chronic granulomatous disease and its possible link to the pathogenesis of cancer. Eur J Cancer. 1996;32A(4):734-5. 84. Lugo Reyes SO, Suarez F, Herbigneaux RM, Pacquement H, Reguerre Y, Riviere JP, et al. Hodgkin lymphoma in 2 children with chronic granulomatous disease. J Allergy Clin Immu-nol. 2011;127(2):543-4 e1-3. 85. Geramizadeh B, Alborzi A, Hosseini M, Ramzi M, Foroutan H. Primary splenic Hodgkin’s disease in a patient with chronic granulomatous disease, a case report. Iranian Red Crescent Medical Journal2010. p. 319-21. 86. Wolach B, Ash S, Gavrieli R, Stark B, Yaniv I, Roos D. Acute lymphoblastic leukemia in a patient with chronic granulomatous disease and a novel mutation in CYBB: first report. Am J Hematol. 2005;80(1):50-4. 87. Aguilera DG, Tomita T, Rajaram V, Fangusaro J, Katz BZ, Shulman S, et al. Glioblastoma multiforme in a patient with chronic granulomatous disease treated with subtotal resection, radiation, and thalidomide: case report of a long-term survivor. J Pediatr Hematol Oncol. 2009;31(12):965-9. 88. Yu JE, Azar AE, Chong HJ, Jongco AM, 3rd, Prince BT. Considerations in the Diagnosis of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S6-S11. 89. Yu JE, Azar AE, Chong HJ, Jongco III AM, Prince BT. Considerations in the diagnosis of chronic granulomatous disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S6-S11. 90. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol. 2010;38(1):3-10. 91. Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis. 1990;162(3):723-6. 92. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348(24):2416-22. 93. Kang EM, Malech HL. Advances in treatment for chronic granulomatous disease. Immunol Res. 2009;43(1-3):77-84. 94. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008;140(3):255-66. 95. Soncini E, Slatter MA, Jones LB, Hughes S, Hodges S, Flood TJ, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol. 2009;145(1):73-83. 96. Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A. 1997;94(22):12133-8. 97. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-9. 98. Kang EM, Choi U, Theobald N, Linton G, Long Priel DA, Kuhns D, et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood. 2010;115(4):783-91.